Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
about
Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic ReviewQuantifying and monitoring overdiagnosis in cancer screening: a systematic review of methodsOverdiagnosis and overtreatment of prostate cancerScreening guidelines for non-AIDS defining cancers in HIV-infected individualsWhole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.Circulating microRNAs: potential biomarkers for common malignanciesEarly detection of prostate cancer: AUA Guideline.Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.The impact of overdiagnosis on the selection of efficient lung cancer screening strategiesPersonalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.Expected population impacts of discontinued prostate-specific antigen screening.Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers.What do the screening trials really tell us and where do we go from here?Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, CanadaInfluence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment StrategiesThe Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.Doctors' perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study.Individualized estimates of overdiagnosis in screen-detected prostate cancer.American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.E-Science technologies in a workflow for personalized medicine using cancer screening as a case study.Prostate-specific antigen-based prostate cancer screening: Past and future.The Effects of Beginning Population Based PSA Screening at Age 40.Site-Specific Fucosylation Analysis Identifying Glycoproteins Associated with Aggressive Prostate Cancer Cell Lines Using Tandem Affinity Enrichments of Intact Glycopeptides Followed by Mass SpectrometryIs prostate cancer different in black men? Answers from 3 natural history models.Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway.Screening Men at Increased Risk for Prostate Cancer Diagnosis: Model Estimates of Benefits and Harms.Prostate cancer: Prudent practice optimizes screening outcomes.The ONCOTYROL Prostate Cancer Outcome and Policy Model: Effect of Prevalence Assumptions on the Benefit-Harm Balance of Screening.Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.A model too far.Implications of the new AUA guidelines on prostate cancer detection in the U.S.Recommandations de l’Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate.Tissue-based biomarkers in prostate cancer.Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.Summary statement on screening for prostate cancer in Europe.Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
P2860
Q26748873-5D83D9BF-3F29-4B85-BAC2-8A8CFDA272DBQ26824867-AB6196B9-EAEF-4E52-A817-0BECA10B695FQ26859596-99EFEA31-F5D8-4428-9EC5-9AC8C62D4D9CQ27021899-9EAC402A-0033-4F77-8842-5D61DFD4845FQ27853196-FECBFD0E-D7E0-4555-866B-E13F10D121D1Q28081347-DDF0DB24-30D4-442F-9572-AF2F64CCDE5AQ33608474-98C0389C-0338-4290-877D-4B4DF0B9DFC0Q33836709-AB0365FF-34ED-4C60-934E-DE1001F88561Q33917618-40CEBA6B-89A0-4277-B061-F9A5983B8115Q34159375-75AF59F5-8389-4A34-A0ED-67886075898AQ34458237-4E96547B-BB61-4DE9-B0BD-B8A4BDD4942EQ34785893-1C18631F-8C71-4144-83D1-D62890666243Q35234770-042C0E0E-A32B-4FD1-9E55-19587ED7731FQ35541638-77AC1C96-7A11-452B-BBEF-EBFFB49C43CCQ37070417-A8909469-A3D4-4C67-A9B7-2F5C1798F064Q37095655-A7C6514C-ACE4-4A46-BEBF-29E32B661A8FQ37103771-C99EE88C-C1E8-402A-9358-74FD9D14FC44Q37106776-98CBE813-F7FA-4E5D-9A60-F88F5E2B88B7Q37517373-1C4713C7-F45D-43A5-9B9F-D07FEB191040Q37634486-FFAEF2F3-2ED9-4A52-B1E8-245E5BE6BC49Q38127277-F74B00C4-4EC1-40F9-B999-FD183FA9E852Q38371172-06116B5A-7BEC-4746-A727-7C5B55CFD206Q38408501-7CFCA005-08ED-48F8-83E3-62AC37F93865Q38607830-298E8861-C21E-47F2-8700-BECF2865EBD2Q38719466-C1D17269-21E1-48D3-B851-ABF77DD21BE1Q38823794-AAC71FBD-9D13-4A7D-A1C9-2EEF90CC3514Q39012041-03460798-8B48-4AFD-AD4E-E42BA973DC41Q39289771-9EF58297-72E7-4F25-9220-1974429CD4A9Q40740497-020A7D49-95DA-4242-B928-12A889AFA19FQ40936828-E486E4C2-D5EB-4545-BC2C-70D67958DE11Q41437748-11A0902C-8692-42F1-9D61-A068EE87D33CQ42395953-FAF34A0A-AB70-449B-BC76-E640AF210B28Q42573803-D3D20808-6CCD-4AE8-8BAF-8EF6E6562794Q46619813-73D5BCDC-F8CF-4FDA-96B9-CF76B89F85D4Q47123251-EA613A17-0EE2-4561-838E-703416C8D463Q47144748-1B659901-FC5A-49A9-A67F-94AE9C152041Q47324732-3D6C1122-33AB-411A-935B-74AEB4F2F0C3Q47358352-E3257E8D-3C02-4105-9321-CA60CD198A1DQ47901606-C170E965-00E2-4951-8919-168ED5AA46B8Q48165110-1A13D4E6-FDF8-490D-A4DC-9B7261B460C4
P2860
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Comparative effectiveness of a ...... potential benefits and harms.
@ast
Comparative effectiveness of a ...... potential benefits and harms.
@en
Comparative effectiveness of a ...... potential benefits and harms.
@nl
type
label
Comparative effectiveness of a ...... potential benefits and harms.
@ast
Comparative effectiveness of a ...... potential benefits and harms.
@en
Comparative effectiveness of a ...... potential benefits and harms.
@nl
prefLabel
Comparative effectiveness of a ...... potential benefits and harms.
@ast
Comparative effectiveness of a ...... potential benefits and harms.
@en
Comparative effectiveness of a ...... potential benefits and harms.
@nl
P2860
P1476
Comparative effectiveness of a ...... potential benefits and harms.
@en
P2093
Roman Gulati
Ruth Etzioni
P2860
P304
P356
10.7326/0003-4819-158-3-201302050-00003
P407
P50
P577
2013-02-01T00:00:00Z